Literature DB >> 27505086

A novel insulin receptor mutation in an adolescent with acanthosis nigricans and hyperandrogenism.

Mansa Krishnamurthy, Mia M Pingul.   

Abstract

Insulin receptor mutations cause extreme insulin resistance resulting in acanthosis nigricans and hyperandrogenism. We report a pre-menarchal adolescent female with normal weight, with severe acanthosis nigricans, acne, and hirsutism. Initial investigation revealed elevated fasting and post-prandial insulin and high testosterone and androstenedione levels. Her father had frequent complaints of hypoglycemia. Coding sequence and splice junction analysis of the INSR gene, in our patient and her father, revealed a heterozygous missense mutation in the β subunit of the insulin receptor (Arg1131Trp), resulting in receptor loss of function. Metformin therapy and carbohydrate control improved acanthosis and menarche ensued within 3 months. Our case highlights the importance of distinguishing insulin resistance commonly associated with obesity from monogenic defects. Although, there is no consensus on treatment of children with monogenic forms of insulin resistance due to its rarity, dietary and lifestyle modifications and insulin-sensitizing agents play a key role in management.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27505086     DOI: 10.1515/jpem-2015-0384

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  2 in total

Review 1.  Insulin Receptor Trafficking: Consequences for Insulin Sensitivity and Diabetes.

Authors:  Yang Chen; Lili Huang; Xinzhou Qi; Chen Chen
Journal:  Int J Mol Sci       Date:  2019-10-10       Impact factor: 5.923

2.  Heterozygous Insulin Receptor (INSR) Mutation Associated with Neonatal Hyperinsulinemic Hypoglycaemia and Familial Diabetes Mellitus: Case Series

Authors:  Aashish Sethi; Nicola Foulds; Sarah Ehtisham; Syed Haris Ahmed; Jayne Houghton; Kevin Colclough; Mohammed Didi; Sarah E. Flanagan; Senthil Senniappan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2020-01-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.